JP2012506411A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506411A5
JP2012506411A5 JP2011532725A JP2011532725A JP2012506411A5 JP 2012506411 A5 JP2012506411 A5 JP 2012506411A5 JP 2011532725 A JP2011532725 A JP 2011532725A JP 2011532725 A JP2011532725 A JP 2011532725A JP 2012506411 A5 JP2012506411 A5 JP 2012506411A5
Authority
JP
Japan
Prior art keywords
factor
binding protein
immune response
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011532725A
Other languages
English (en)
Japanese (ja)
Other versions
JP5676458B2 (ja
JP2012506411A (ja
Filing date
Publication date
Priority claimed from GBGB0819633.9A external-priority patent/GB0819633D0/en
Application filed filed Critical
Publication of JP2012506411A publication Critical patent/JP2012506411A/ja
Publication of JP2012506411A5 publication Critical patent/JP2012506411A5/ja
Application granted granted Critical
Publication of JP5676458B2 publication Critical patent/JP5676458B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011532725A 2008-10-25 2009-10-26 変異h因子結合タンパク質を含むワクチン組成物 Expired - Fee Related JP5676458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0819633.9A GB0819633D0 (en) 2008-10-25 2008-10-25 Composition
GB0819633.9 2008-10-25
PCT/GB2009/051439 WO2010046715A1 (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014261910A Division JP6076326B2 (ja) 2008-10-25 2014-12-25 変異h因子結合タンパク質を含むワクチン組成物

Publications (3)

Publication Number Publication Date
JP2012506411A JP2012506411A (ja) 2012-03-15
JP2012506411A5 true JP2012506411A5 (enExample) 2012-12-06
JP5676458B2 JP5676458B2 (ja) 2015-02-25

Family

ID=40133849

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011532725A Expired - Fee Related JP5676458B2 (ja) 2008-10-25 2009-10-26 変異h因子結合タンパク質を含むワクチン組成物
JP2014261910A Expired - Fee Related JP6076326B2 (ja) 2008-10-25 2014-12-25 変異h因子結合タンパク質を含むワクチン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014261910A Expired - Fee Related JP6076326B2 (ja) 2008-10-25 2014-12-25 変異h因子結合タンパク質を含むワクチン組成物

Country Status (23)

Country Link
US (1) US20120052092A1 (enExample)
EP (2) EP3501534B1 (enExample)
JP (2) JP5676458B2 (enExample)
KR (3) KR20170000390A (enExample)
CN (2) CN105412920A (enExample)
AU (1) AU2009306114B2 (enExample)
BR (1) BRPI0919926A2 (enExample)
CA (1) CA2741619A1 (enExample)
CO (1) CO6382140A2 (enExample)
DK (1) DK3501534T5 (enExample)
ES (1) ES2970878T3 (enExample)
FI (1) FI3501534T3 (enExample)
GB (1) GB0819633D0 (enExample)
HR (1) HRP20240226T1 (enExample)
HU (1) HUE065348T2 (enExample)
LT (1) LT3501534T (enExample)
MX (1) MX2011004322A (enExample)
NZ (2) NZ592444A (enExample)
PL (1) PL3501534T3 (enExample)
PT (1) PT3501534T (enExample)
RU (1) RU2559528C2 (enExample)
SI (1) SI3501534T1 (enExample)
WO (1) WO2010046715A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261341A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
EP1860191A3 (en) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
EP2275552B1 (en) 1999-10-29 2015-09-09 GlaxoSmithKline Biologicals SA Neisserial antigenic peptides
CN101139590B (zh) 2000-02-28 2012-07-18 启龙股份公司 奈瑟球菌蛋白质的杂交表达
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
ES2797504T3 (es) 2009-03-24 2020-12-02 Glaxosmithkline Biologicals Sa Proteína de enlace del factor H meningocócico utilizada como adyuvante
NZ595361A (en) 2009-04-30 2013-09-27 Childrens Hosp & Res Ct Oak Chimeric factor h binding proteins (fhbp) and methods of use
EP2493499A1 (en) * 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
JP2013521326A (ja) * 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014140562A1 (en) * 2013-03-14 2014-09-18 Isis Innovation Limited Immunogenic composition to neisseria
CA2918547A1 (en) 2013-08-02 2015-02-05 Peter T. Beernink Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
KR102761870B1 (ko) 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
KR102709811B1 (ko) * 2014-08-20 2024-09-24 스티흐팅 산퀸 불드포르지닝 인자 h 강화 항체 및 그의 용도
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
CN113453709A (zh) 2018-12-21 2021-09-28 格里菲斯大学 用于引发免疫应答的组合物、方法和用途
JP2022541757A (ja) * 2019-07-08 2022-09-27 クラポード バイオ,インコーポレイテッド リポオリゴ糖組成物およびワクチンの製造および使用方法
KR20220057530A (ko) 2019-07-17 2022-05-09 제미니 테라퓨틱스 서브, 인코포레이티드 인자 h 강화 항체 및 이의 용도
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP1618185A4 (en) * 2003-04-16 2009-05-27 Wyeth Corp NEW IMMUNOLOGICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCOULAR DISEASE
DK2682126T3 (en) * 2005-01-27 2017-02-27 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2008001224A2 (en) * 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
BR112012004275A2 (pt) * 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
BR122021020829B8 (pt) * 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada

Similar Documents

Publication Publication Date Title
JP2012506411A5 (enExample)
RU2011120706A (ru) Композиции вакцин, содержащие мутированный белок, связывающий фактор н
TWI355390B (en) Immunogenic peptide carrier conjugates and methods
JP2013542224A5 (enExample)
Silin et al. Oral vaccination: where we are?
HU229968B1 (hu) Sztreptokokkusz oltóanyag
JP6909728B2 (ja) 弱毒化細菌によって送達されるリコール抗原を使用する癌の治療
ES2748381T3 (es) Polipéptido(s) llevado(s) por CYAA y uso para inducir respuestas inmunitarias terapéuticas y profilácticas
TW202038996A (zh) 包含肺炎鏈球菌多醣-蛋白質共軛物之組合物及其使用方法
NO20076239L (no) Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom
ES2257769T3 (es) Metodo para la preparacion de vacunas multivalentes.
JP2010500399A5 (enExample)
KR20180054629A (ko) 장외 병원성 e. 콜리에 대한 면역 보호를 위한 방법 및 조성물
RU2013117082A (ru) Иммуногенные композиции
CN101421299A (zh) 用于诱导产生抗淀粉样β肽抗体的肽疫苗
US20150258190A1 (en) Nicotinamide as adjuvant
JP2014508734A5 (enExample)
TW201440786A (zh) 無細胞百日咳疫苗
JP2016523912A (ja) デングウイルスワクチンのための方法および組成物
JP2009539821A (ja) ワクチンの舌下投与用医薬組成物、その調製方法およびその使用
JP2020536925A5 (enExample)
US10933126B2 (en) Clostridium difficile immunogenic compositions and methods of use
WO2004028549A1 (en) A coixenolide capsules for treating prostate disease
US12097254B2 (en) Rabies composition comprising PIKA adjuvant
WO2000012718A1 (en) Superoxide dismutase as a vaccine antigen